Scholar Rock Q3 2026 net loss widens to $107.24 million

• Scholar Rock’s third-quarter 2026 net loss widened year over year to $107.24 million.
• Net product revenue reached $570,000, with ISEMBYLD shipped to the specialty network before quarter-end.
• ISEMBYLD’s U.S. launch is underway following September 11 FDA approval; initial patients received infusions in October.
• Cash, cash equivalents and marketable securities totaled $413.6 million at September 30, 2026.
• In November, the company agreed to sell its Rare Pediatric Disease Priority Review Voucher for $205 million, payable upon closing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scholar Rock Holding Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202611100700BIZWIRE_USPR_____20261110_BW252867) on November 10, 2026, and is solely responsible for the information contained therein.